Pharmaceuticals giant GSK plc, listed in London and New York, has appointed Luke Miels as CEO designate. He will assume full responsibilities as CEO and join the board on 1^st January 2026.

Miels joined GSK in 2017 and is currently chief commercial officer, with worldwide responsibility for medicines and vaccines. He has previously worked at senior levels in the US, Europe and Asia at AstraZeneca, Roche and Sanofi-Aventis.

He will succeed Dame Emma Walmsley, who is said to have transformed the business during her nine years at the helm.